CMC ICOS Biologics and Harpoon Therapeutics have entered into an agreement for the development and manufacture of HPN424, HPN536, and HPN217, three TriTAC molecules in development for the treatment of various cancers. 
Harpoon’s TriTAC molecules are half-life extended and designed to simultaneously bind to cancer cells and T-cells, triggering those T-cells to attack the targeted cancer cells. These molecules contain three binding domains: one binds a specific tumor target, one binds to human ...